NCT07223814
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07223814
Title Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Stichting Hemato-Oncologie voor Volwassenen Nederland
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | NLD | DEU

Facility Status City State Zip Country Details
US-Cincinnati OH-CINCY RECRUITING Cincinnati Ohio 45219 United States Details
DE-Ulm-UNIKLINKULM RECRUITING Ulm Germany Details
NL-Breda-AMPHIA RECRUITING Breda Netherlands Details
NL-Eindhoven-MAXIMAMC RECRUITING Eindhoven Netherlands Details
NL-Leeuwarden-FRISIUSMC RECRUITING Leeuwarden Netherlands Details
NL-Nieuwegein-ANTONIUS RECRUITING Nieuwegein Netherlands Details
NL-Rotterdam-ERASMUCMC RECRUITING Rotterdam Netherlands Details
NL-Den Haag-HAGA RECRUITING The Hague Netherlands Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field